サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536176

胸膜炎治療の世界市場

Pleurodynia Treatment

出版日
ページ情報
英文 270 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
胸膜炎治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胸膜炎治療の世界市場は2030年までに1億2,000万米ドルに達する見込み

2023年に9,660万米ドルと推定される胸膜炎治療の世界市場は、2030年には1億2,000万米ドルに達し、分析期間2023-2030年のCAGRは3.1%で成長すると予測されます。本レポートで分析したセグメントの1つである鎮痛剤療法は、CAGR 3.5%を記録し、分析期間終了時には7,030万米ドルに達すると予測されます。免疫グロブリン療法分野の成長率は、分析期間中CAGR 2.7％と推定されます。

米国市場は2,630万米ドルと推定、中国はCAGR6.1%で成長予測

米国の胸膜炎治療市場は2023年に2,630万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 6.1%で成長し、2030年には市場規模2,460万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.0％と2.4％と予測されています。欧州では、ドイツがCAGR 1.6%で成長すると予測されています。

世界の胸膜炎治療市場- 主要動向と促進要因まとめ

ボーンホルム病としても知られる胸膜炎は、コクサッキーBウイルスによって引き起こされる急性のウイルス感染症です。肋骨周囲の筋肉の炎症（胸膜炎）による突然の激しい胸痛や腹痛が特徴です。症状には発熱、頭痛、筋肉の圧痛が含まれることが多く、痛みは深呼吸、咳、動作によって増悪することがあります。胸膜炎は主に小児や若年成人が罹患し、通常1～2週間で自然に治ります。しかし、激しい疼痛と不快感を引き起こすため、症状を緩和し、患者のQOLを改善するための効果的な疼痛管理と治療戦略が必要となります。

胸膜炎の治療には、症状が自己限定的でウイルス性であることから、症状の緩和が第一のアプローチとなります。イブプロフェンやナプロキセンなどの非ステロイド性抗炎症薬（NSAIDs）が痛みと炎症を抑えるために一般的に処方されます。痛みが強い場合は、ヘルスケア担当者がより強い鎮痛剤や筋弛緩剤を勧めることもあります。安静と十分な水分補給も治療には欠かせません。特に免疫系が低下している患者さんでは、抗ウイルス薬が考慮される場合もあります。さらに、温湿布や呼吸法などの支持療法は、筋肉の不快感を和らげ、呼吸機能を改善するのに役立ちます。

胸膜炎治療市場の成長は、いくつかの要因によってもたらされます。第一に、認知度の向上と診断能力の向上により、胸膜透析がより頻繁かつ正確に特定されるようになり、効果的な治療に対する需要が高まっています。第二に、製薬研究の進歩により、より強力で標的を絞った非ステロイド性抗炎症薬や疼痛管理ソリューションが開発され、患者の転帰が向上しています。人口の増加や旅行者の増加もあり、世界的にウイルス感染症が増加していることも市場拡大に寄与しています。さらに、特に新興国ではヘルスケア・インフラが整備されたことで、治療へのアクセスが広がっています。個別化医療やオーダーメイドの治療計画を目指す動向は、胸膜炎に特化した治療法の開発を後押ししています。最後に、製薬企業と研究機関の戦略的提携により、新規治療法の発見が加速しており、市場に参入する新規治療法の安定したパイプラインが確保されています。

調査対象企業の例（全86件）

  • Algen Healthcare Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Estrellas Life Sciences Pvt. Ltd.
  • GSK Plc
  • Healthy Life Pharma（P）Ltd.
  • Horizon Therapeutics plc
  • Lifecare Neuro Products Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zyla Life Sciences;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26611

Global Pleurodynia Treatment Market to Reach US$120.0 Million by 2030

The global market for Pleurodynia Treatment estimated at US$96.6 Million in the year 2023, is expected to reach US$120.0 Million by 2030, growing at a CAGR of 3.1% over the analysis period 2023-2030. Painkillers Therapy, one of the segments analyzed in the report, is expected to record a 3.5% CAGR and reach US$70.3 Million by the end of the analysis period. Growth in the Immunoglobulin Therapy segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$26.3 Million While China is Forecast to Grow at 6.1% CAGR

The Pleurodynia Treatment market in the U.S. is estimated at US$26.3 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$24.6 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Pleurodynia Treatment Market - Key Trends and Drivers Summarized

Pleurodynia, also known as Bornholm disease, is an acute viral infection caused by the Coxsackie B virus. It is characterized by sudden, intense chest or abdominal pain due to inflammation of the muscles around the ribs (pleurisy). Symptoms often include fever, headache, and muscle tenderness, with pain that can be exacerbated by deep breathing, coughing, or movement. Pleurodynia primarily affects children and young adults and typically resolves on its own within a week or two. However, the severe pain and discomfort it causes necessitate effective management and treatment strategies to alleviate symptoms and improve patient quality of life.

The primary approach to treating pleurodynia involves symptomatic relief, as the condition is self-limiting and viral in nature. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen are commonly prescribed to reduce pain and inflammation. In cases of severe pain, healthcare providers may recommend stronger analgesics or muscle relaxants. Rest and adequate hydration are also essential components of the treatment regimen. In some instances, antiviral medications may be considered, particularly in patients with compromised immune systems. Additionally, supportive therapies, such as warm compresses and breathing exercises, can help ease muscle discomfort and improve respiratory function.

The growth in the pleurodynia treatment market is driven by several factors. Firstly, increased awareness and better diagnostic capabilities have led to more frequent and accurate identification of pleurodynia, boosting demand for effective treatments. Secondly, advancements in pharmaceutical research have resulted in the development of more potent and targeted NSAIDs and pain management solutions, enhancing patient outcomes. The rise in the global incidence of viral infections, partly due to population growth and increased travel, has also contributed to market expansion. Furthermore, improved healthcare infrastructure, particularly in emerging economies, has made access to treatment more widespread. The trend towards personalized medicine and tailored treatment plans has encouraged the development of specialized therapies for pleurodynia. Lastly, strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery of novel treatment options, ensuring a steady pipeline of new therapies entering the market.

Select Competitors (Total 86 Featured) -

  • Algen Healthcare Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Co., Ltd.
  • Estrellas Life Sciences Pvt. Ltd.
  • GSK Plc
  • Healthy Life Pharma (P) Ltd.
  • Horizon Therapeutics plc
  • Lifecare Neuro Products Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zyla Life Sciences;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Pleurodynia Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Awareness of Pleurodynia Throws the Spotlight on Treatment Demand
    • Advancements in Diagnostic Technologies Propel Growth in Pleurodynia Treatment Market
    • Rising Incidence of Viral Infections Generates Demand for Effective Treatments
    • Expanding Research in Antiviral Therapies Sustains Growth in Treatment Options
    • Growing Popularity of Non-Invasive Treatment Methods Spurs Market Expansion
    • Pharmaceutical Investments in Novel Drug Development Enhance Market Opportunities
    • Increasing Incidence of Post-Viral Syndromes Expands Addressable Market Opportunity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pleurodynia Treatment Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pleurodynia Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Painkillers Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Painkillers Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Immunoglobulin Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Immunoglobulin Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Pleurodynia Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • FRANCE
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Pleurodynia Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • INDIA
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Pleurodynia Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Pleurodynia Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Pleurodynia Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030
  • AFRICA
    • Pleurodynia Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Pleurodynia Treatment by Therapy - Painkillers Therapy and Immunoglobulin Therapy Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Pleurodynia Treatment by Therapy - Percentage Breakdown of Value Sales for Painkillers Therapy and Immunoglobulin Therapy for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Pleurodynia Treatment by End-Use - Hospitals End-Use, Pharmacies End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Pleurodynia Treatment by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Pharmacies End-Use and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION